Patents Assigned to Yamaguchi University
-
Publication number: 20240154117Abstract: Provided are a sodium titanium phosphate salt and, additionally, at least one of a negative electrode active material that gives a sodium secondary battery having superior power characteristics as compared to conventional aqueous sodium secondary batteries and a sodium secondary battery including such a negative electrode active material. In particular, provided is a negative electrode active material that gives an aqueous sodium secondary battery having superior power characteristics as compared to conventional aqueous sodium secondary batteries including NASICON type NaTi2(PO4)3 as a negative electrode active material. A sodium titanium phosphate salt represented by the general formula Na1+xTi2(PO4)3 (where 0?x?2) includes a surface layer containing Na5Ti(PO4)3.Type: ApplicationFiled: March 2, 2022Publication date: May 9, 2024Applicants: YAMAGUCHI UNIVERSITY, TOSOH CORPORATIONInventors: Ayuko KITAJOU, Maho YAMASHITA, Masaki OKADA, Wataru KOBAYASHI, Toshiya TAKAHARA
-
Publication number: 20240113338Abstract: A lithium ion secondary battery includes a negative electrode including a mixture layer which contains a niobium titanium oxide as a negative electrode active material, and non-aqueous electrolyte containing lithium alkoxysulfonate represented by RSOOO?Li+ (where R is at least one selected from the group consisting of OCH3 and OC2H5).Type: ApplicationFiled: November 16, 2023Publication date: April 4, 2024Applicants: The Furukawa Battery Co., Ltd., YAMAGUCHI UNIVERSITYInventors: Yosuke Masuda, Miyu Nemoto, Hiroatsu Kondou, Koji Abe, Yanko Marinov Todorov
-
Patent number: 11931381Abstract: It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.Type: GrantFiled: May 19, 2022Date of Patent: March 19, 2024Assignee: YAMAGUCHI UNIVERSITYInventors: Koji Tamada, Yukimi Sakoda, Keishi Adachi
-
Publication number: 20240052333Abstract: The present invention has an object to provide a D-mannose isomerase of membrane-bound form having the optimal reaction pH in acidic region. The membrane-bound D-mannose isomerase derived from acetic acid bacteria is produced. The acetic acid bacteria are preferably belong to the genera of Acetobacter, Gluconobacter, or Gluconacetobacter. Furthermore, the membrane-bound D-mannose isomerase from the acetic acid bacteria is used to produce D-fructose from D-mannose.Type: ApplicationFiled: December 28, 2021Publication date: February 15, 2024Applicant: YAMAGUCHI UNIVERSITYInventors: Osao Adachi, Toshiharu Yakushi, Naoya Kataoka, Kazunobu Matsushita
-
Publication number: 20240026430Abstract: An object of the present invention is to provide a method for amplifying a nucleic acid using a PCR reaction solution with a volume as large as 30 mL or more, and an apparatus for amplifying a nucleic acid using a PCR reaction solution with a volume as large as 30 mL or more. The present invention provides a method for amplifying a nucleic acid, comprising performing polymerase chain reaction (PCR) by controlling a temperature of one or more reaction container(s) housing a reaction solution containing a DNA polymerase, deoxyribonucleotide triphosphates (dNTPs), a template DNA, a forward primer, a reverse primer, and a buffer solution, wherein the reaction solution is in an amount of 30 mL or more, and the polymerase chain reaction is performed while the reaction solution is stirred.Type: ApplicationFiled: February 25, 2021Publication date: January 25, 2024Applicants: YAMAGUCHI UNIVERSITY, YANAGIYA MACHINERY CO., LTD.Inventors: Tetsunori Fujimoto, Noriatsu Nakata, Tadashi Nakatomi, Rinji Akada
-
Publication number: 20240018224Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: ApplicationFiled: June 15, 2023Publication date: January 18, 2024Applicants: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji TAMADA, Yukimi SAKODA, Tetsuya NAKATSURA, Keigo SAITO
-
Publication number: 20230322898Abstract: The present invention provides a pharmaceutical composition comprising cells expressing a chimeric receptor, for use in combination with administration of an antigen-binding molecule, wherein the chimeric receptor comprises an extracellular domain, the extracellular domain comprises an extracellular domain of an immunoreceptor, an extracellular domain variant of an immunoreceptor, or a portion thereof, and the antigen-binding molecule is a multispecific antigen-binding molecule having a target antigen recognition site and an immunoreceptor recognition site which recognizes the immunoreceptor.Type: ApplicationFiled: July 30, 2021Publication date: October 12, 2023Applicants: Chugai Seiyaku Kabushiki Kaisha, Yamaguchi UniversityInventors: Tomoyuki Igawa, Mika Sakurai, Takashi Suzuki, Kanako Tatsumi, Shun Shimizu, Koji Tamada, Yukimi Sakoda
-
Publication number: 20230302082Abstract: It is an object of the present invention to provide a reversible opening agent for the neural vascular barrier. As a solution, the reversible opening agent for the neural vascular barrier is prepared by including a ligand having an agonistic effect on basigin as an active ingredient. It is preferable that the above ligand contains a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 1 or the like, or a salt thereof as the active ingredient or the above ligand is cyclophilin A lacking peptidyl-prolyl cis-trans isomerase activity.Type: ApplicationFiled: August 19, 2021Publication date: September 28, 2023Applicant: YAMAGUCHI UNIVERSITYInventor: Eiji Ikeda
-
Publication number: 20230280277Abstract: An elongated ferromagnetic anodic electrode is fixed to a tightly closable pipe shape vacuum casing so as to extend within the casing as a cantilever and magnetic field applying module is disposed so as to concentrate magnetic field at a tip side position of the ferromagnetic anodic electrode in an area of discharge optical emission when a high voltage is applied between the anodic electrode and the vacuum casing as a cathode electrode. In addition, a vacuum casing can be formed with a ferromagnetic and soft magnetic material for magnetic flux to be permeable well, or a tip side alone of an anodic electrode rather than the anodic electrode itself can be formed with a ferromagnetic material, or a ferromagnetic member can be disposed at a near position of an anodic electrode, so as to concentrate magnetic field in a vicinity of a tip of an anodic electrode.Type: ApplicationFiled: May 10, 2023Publication date: September 7, 2023Applicants: Marunaka Co.,Ltd., Sanko Ematec Co., Ltd., YAMAGUCHI UNIVERSITYInventors: Mitsugu NAKAGAWA, Kazumi ENOMOTO, Setsuo YAMAMOTO, Hiroki KURISU
-
Patent number: 11730718Abstract: The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.Type: GrantFiled: June 4, 2020Date of Patent: August 22, 2023Assignee: YAMAGUCHI UNIVERSITYInventor: Kazuhiro Kimura
-
Publication number: 20230258509Abstract: For measuring the stress history in a simple form, which is widely applicable to various types of structural materials which the elastic modulus is different from each other, a large number of calcite particles is embedded as a stress sensor in a cement-based composite material that can be elastically deformed after receiving an external. A twin-crystal density of the calcite particles is measured after an external force is applied to the composite material, to convert the twin-crystal density to a strain by an approximate formula set in terms of a strain ? (%) generated in the composite material and a twin-crystal density Dtw (lines/mm) of the calcite particles, and further to convert this strain to a stress by the elastic modulus of the composite material, whereby to estimate the history of stress and strain. The approximate formula between strain and twin-crystal density is independent of the modulus of the composite material and is used in a common form.Type: ApplicationFiled: July 8, 2021Publication date: August 17, 2023Applicant: YAMAGUCHI UNIVERSITYInventors: Arito SAKAGUCHI, Kouhei ANDO
-
Patent number: 11718663Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: GrantFiled: January 10, 2018Date of Patent: August 8, 2023Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
-
Patent number: 11692216Abstract: An object of the present invention is to provide a simple and efficient device for predicting a risk of occurrence of a side effect of irinotecan by analyzing a single nucleotide polymorphism in a region encoding a specific gene. The prediction of the risk of the occurrence of a side effect of irinotecan is assisted by analyzing a single nucleotide polymorphism in a region encoding the APCDD1L gene, the R3HCC1 gene, the OR51I2 gene, the MKKS gene, the EDEM3 gene, or the ACOX1 gene which are present on genomic DNA in a biological sample collected from a test subject; or a single nucleotide polymorphism which is in linkage disequilibrium with or genetically linked to the single nucleotide polymorphism, and determining whether the single nucleotide polymorphism is homozygous for a variant type, heterozygous, or homozygous for a wild-type.Type: GrantFiled: February 12, 2020Date of Patent: July 4, 2023Assignees: YAMAGUCHI UNIVERSITY, TOYO KOHAN CO., LTD.Inventors: Masaaki Oka, Shoichi Hazama, Ryouichi Tsunedomi
-
Patent number: 11670398Abstract: It is intended to conveniently determine the pharmacokinetics of axitinib and to predict the therapeutic effect of axitinib. The present invention provides a method for determining the pharmacokinetics of axitinib, comprising the step of calculating a predicted pharmacokinetic parameter of axitinib using specific gene polymorphisms and background factors regarding a test subject.Type: GrantFiled: May 18, 2018Date of Patent: June 6, 2023Assignees: Yamaguchi University, Toyo Kohan Co., Ltd.Inventors: Hideyasu Matsuyama, Yoshihiko Hamamoto, Yusuke Fujita, Yoshiaki Yamamoto, Ryouichi Tsunedomi, Mitsuyoshi Oba, Hirofumi Yamano, Yukiha Ishikawa
-
Patent number: 11655298Abstract: It is an object to provide effective means for preventing and/or treating fulminant acute pneumonia. Provided are a pharmaceutical agent or pharmaceutical composition to be used for preventing and/or treating fulminant acute pneumonia, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing intra-alveolar neutrophil aggregation, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing pulmonary neutrophil infiltration, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), and a method of preventing and/or treating fulminant acute pneumonia, including administering a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody).Type: GrantFiled: October 20, 2017Date of Patent: May 23, 2023Assignees: YAMAGUCHI UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Akihiro Hasegawa, Hidetaka Ogino, Toshinori Nakayama
-
Patent number: 11617765Abstract: An object of the present invention is to provide an enhancer for endogenous T-cells or B-cells having a memory function and a malignant tumor recurrence inhibitor in order to continue to reject malignant tumor over a long period of time. An enhancer for T-cells or B-cells having a memory function in an administration subject, comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and an inducer for inducing a memory function in T-cells or B-cells in an administration subject, are prepared. Also, a malignant tumor recurrence inhibitor comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding CCL19, is prepared.Type: GrantFiled: October 9, 2018Date of Patent: April 4, 2023Assignees: Yamaguchi University, National University Corporation Totori UniversityInventors: Koji Tamada, Yukimi Sakoda, Keishi Adachi, Takafumi Nakamura
-
Patent number: 11471440Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.Type: GrantFiled: December 2, 2019Date of Patent: October 18, 2022Assignee: YAMAGUCHI UNIVERSITYInventor: Kazuhiro Kimura
-
Publication number: 20220324975Abstract: The present disclosure provides a pharmaceutical composition comprising an antibody having ADCC activity, a T cell-redirecting antibody, or a cell expressing a chimeric receptor, for use in combination with the administration of an antigen binding molecule capable of binding to a target antigen, wherein the primary molecule comprises a linker that is cleaved by protease, the antigen binding molecule obtained through the cleavage of the linker has the ability to bind to the target antigen, variable regions of the antibody having ADCC activity or the T cell-redirecting antibody, and an extracellular binding domain of the chimeric receptor bind to a cell expressing the target antigen via binding to the antigen binding molecule resulting from the cleavage of the cleavable linker.Type: ApplicationFiled: June 5, 2020Publication date: October 13, 2022Applicants: Chugai Seiyaku Kabushiki Kaisha, Yamaguchi UniversityInventors: Mika Sakurai, Tomoyuki Igawa, Yasunori Komori, Koji Tamada, Yukimi Sakoda
-
Patent number: 11461598Abstract: An information processor can logically support prediction based on past statistical information even though the information contains qualitative or non-numerical data. The processor determines whether an input pattern corresponding to an input object (a determination target) belongs to a specific class among multiple classes, based on feature subsets of any combination of a plurality of features, each feature comprises multiple categories. The processor includes a storage storing the input pattern corresponding to the input object and samples corresponding to respective sample objects and a classification determiner determining whether the input pattern belongs to the specific class.Type: GrantFiled: December 26, 2016Date of Patent: October 4, 2022Assignee: YAMAGUCHI UNIVERSITYInventors: Yoshihiko Hamamoto, Horiyuki Ogihara, Norio Iizuka, Takao Tamesa, Masaaki Oka
-
Patent number: 11447752Abstract: Disclosed is a method for producing an in vitro model for blood-brain barrier, including (a) a culturing conditionally immortalized astrocytes on one surface of a porous membrane and culturing conditionally immortalized brain pericytes on the other surface of the porous membrane, until both of the cells become a sheet; (b) culturing conditionally immortalized brain microvascular endothelial cells in a culture vessel, until the cells become a sheet; (c) peeling off the sheet of conditionally immortalized brain microvascular endothelial cells; (d) allowing the sheet of conditionally immortalized brain microvascular endothelial cells to come into contact with the sheet of conditionally immortalized brain pericytes, so that the sheets are arranged in layers; and (e) co-culturing a cell culture comprising three layers consisting of the sheet of conditionally immortalized brain microvascular endothelial cells, the sheet of conditionally immortalized brain pericytes, and the sheet of conditionally immortalized astroType: GrantFiled: March 22, 2017Date of Patent: September 20, 2022Assignee: YAMAGUCHI UNIVERSITYInventors: Yukio Takeshita, Takashi Kanda